Andrew M. Dahlem

Andrew M. Dahlem is a seasoned professional in the fields of clinical pharmacology and drug development, currently serving as a Board Member at Syra Health since October 2023 and as Co-Founder and Advisor at Gate Neurosciences, Inc. since April 2019. Andrew has been the President of Dr. Dahlem Consulting, LLC since May 2018 and previously held significant academic and leadership roles at Indiana University School of Medicine, advancing research and education in clinical pharmacology. Notably, Andrew's extensive career at Eli Lilly and Company from 1990 to January 2018 included various senior leadership positions, overseeing research operations and the toxicology division across multiple regions. Andrew earned a PhD in Toxicology and Drug Metabolism from the University of Illinois Urbana-Champaign and a BS in Biology from The Ohio State University.